Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Reports Slight Revenue Increase, Narrowing Losses

NEW YORK, Feb. 26 (GenomeWeb News) - Orchid BioSciences recorded slightly increased revenues and narrowing losses for the fourth quarter of 2003, the company said today.


Revenues were $13.7 million, up from $13 million during the same period a year ago.


R&D costs decreased sharply, to $0.2 million, from $3 million during the fourth quarter of 2002. This is primarily a result of Orchid's divesture of its SNP genotyping instrumentation business, and of strategic changes of its GeneShield business, according to the company.


The company's net loss amounted to $7.3 million, or $.09 per share, down from $35.1 million, or $.63 per share, during the year-ago period.


As of Dec. 31, Orchid had $9.9 million in cash and cash equivalents.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.